BURLINGTON, Mass., April 18, 2013 /PRNewswire/ -- Decision Resources Group is pleased to announce a distinguished lineup of speakers who will be joining its well-regarded Competitive Landscape Seminar Series focusing on Biologics and Biosimilars on May 2, 2013 at the Hotel Solamar in San Diego, CA. The panel discussion will focus on the key issues affecting the success of the biologics and biosimilars market. Panelists will share their thoughts on market access for biosimilars, the role of indication extrapolation and automatic substitution, as well as their perspective on appropriate pricing models for brands and biosimilars as this dynamic market segment continues to evolve.
Moderated by Andrew Merron , Ph.D., Senior Director, Biosimilars Research, BioTrends Research Group, panelists include:
Panelists will focus on the key issues affecting the biologics landscape and the emerging biosimilars sector based on the European experience of biosimilars to date and expectations for the U.S. Topics to be discussed will include the anticipated future trends in the biologics market and the challenges and drivers of biosimilar adoption in the U.S.
This Decision Resources Group Competitive Landscape Seminar is a one-day strategic informational event covering key issues in the biologics and biosimilars market and will include presentations from six prominent DRG analysts. The seminar is intended for pharmaceutical professionals involved in market research, business development and competitive intelligence. Attendees are invited to engage with analysts and peers with a post-event reception.
For more information and to register, please visit:
Media interested in attending the seminar should contact Roy Strunin at firstname.lastname@example.org or 781-993-2515 for additional information.
About the Competitive Landscape Seminar Series
The Competitive Landscape Seminar Series: Biologics and Biosimilars will be held on May 2, 2013. This high-value, one-day seminar has been developed specifically for biopharmaceutical market research executives as well as biologics and biosimilars product teams. Expert analysts from Decision Resources Group companies—Decision Resources and BioTrends Research Group—will share their latest research findings on key biologics and biosimilars trends.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
|SOURCE Decision Resources Group|
Copyright©2012 PR Newswire.
All rights reserved